Trevena Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain Feb 13, 2012 8:30 am EST
Trevena Receives Research Funding for Parkinson’s Disease from The Michael J. Fox Foundation Dec 19, 2011 8:30 am EST
Cardiorenal Actions of Trevena Biased Ligand Heart Failure Drug Explained in Mayo Clinic Publication and Presentations Sep 12, 2011 9:00 am EDT
Trevena Receives Major New Award from NIH To Develop Delta Opioid Biased Ligand Drug Aug 18, 2011 4:51 pm EDT
Trevena CEO, Maxine Gowen, Ph.D., Named "Best Executive" at Annual Stevie(R) Awards Ceremony Nov 18, 2010 7:00 am EST